Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation
Lubiprostone helps relieve constipation in short-term 4-week studies. There are limited data on long-term pharmacological treatment with lubiprostone for chronic idiopathic constipation.
To examine the long-term safety and effectiveness of lubiprostone in patients with chronic idiopathic constipation.
In this prospective, multicenter, open-labeled trial, 248 patients aged ≥18 years with chronic idiopathic constipation were directed to take lubiprostone 24 mcg BID as needed for 48 weeks. Patients were allowed to decrease the dose in response to the perceived severity of constipation and need for relief. Hematology and chemistry profiles and assessment of constipation symptoms and its severity were performed at all visits. Adverse events (AEs) were recorded.
Of the 248 patients who entered the trial, 127 (51%) completed the trial. A dose reduction was observed in 17% of the patients, resulting in an average study medication exposure across the study of approximately 1.7 capsules (or approximately 40.8 mcg) per day. The most common treatment-related AEs were nausea (19.8%), diarrhea (9.7%), abdominal distension (6.9%), headache (6.9%), and abdominal pain (5.2%). No deaths were reported and of the 16 reported serious AEs, one was considered possibly treatment related. Average changes in serum electrolytes were not clinically relevant at any time point during the study. On average, lubiprostone significantly (p < 0.0001) reduced patient-reported constipation severity, abdominal bloating, and abdominal discomfort across 48 weeks when compared to baseline.
During this 48-week open-label study, lubiprostone was well tolerated. Bowel symptoms consistently improved over 48 weeks in adult patients with chronic idiopathic constipation.
- Sonnenberg A, Koch TR. Epidemiology of constipation in the United States. Dis Colon Rectum. 1989;32:1–8. CrossRef
- Stewart W, Liberman J, Sandler RS, et al. Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol. 1999;94:3530–3540. CrossRef
- Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750–759. CrossRef
- Martin BC. National estimates of office and emergency room constipation-related visits in the United States. Am J Gastroenterol. 2004;99:S244. Abstract. CrossRef
- Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101:927–934.
- Talley NJ. Differentiating functional constipation from constipation-predominant irritable bowel syndrome: management implications. Rev Gastroenterol Disord. 2005;5:1–9.
- Muller-Lissner SA, Kamm MA, Scarpignato C, et al. Myths and misconceptions about chronic constipation. Am J Gastroenterol. 2005;100:232–242. CrossRef
- Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum. 2001;44:1201–1209. CrossRef
- Brandt LJ, Prather CM, Quigley EM, Schiller LR, Schoenfeld P, Talley NJ. Systematic review on the management of chronic constipation in North America. Am J Gastroenterol. 2005;100:S5–S21. CrossRef
- Lacy BE, Chey WD. Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. Expert Opin Pharmacother. 2009;10:143–152. CrossRef
- MiraLAX. Package insert, Schering-Plough HealthCare Products Inc. 2011.
- Jentsch TJ, Poet M, Fuhrmann JC, Zdebik AA. Physiological functions of ClC Cl- channels gleaned from human genetic disease and mouse models. Annu Rev Physiol. 2005;67:779–807. CrossRef
- Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol. 2004;287:C1178–C1183. CrossRef
- Ueno R, Osama H, Habe T, et al. Oral spi-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels (abstract). Gastroenterology. 2004;126:A-100.
- Camilleri M, Bharucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointes Liver Physiol. 2006;290:G942–G947. CrossRef
- Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177. CrossRef
- Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–1097. CrossRef
- Johanson JF, Gargano MA, Holland PC, et al. Phase III, randomized withdrawal study of RU-0211, a novel chloride channel activator for the treatment of constipation. Gastroenterology. 2004;126:A-100. Abstract.
- International Conference on Harmonization. The extent of population exposure to assess clinical safety for drugs for long-term treatment of non-life-threatening conditions. 1994. Available at: http://wwwichorg/cache/compo/475-272-1html#E1.
- Rivera E, Wahle A, Joswick TR, et al. Lubiprostone, a novel type-2 chloride channel (ClC-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterology. 2007;132:A191–A192. Abstract.
- Sprenger C, Copa A, Morganroth J, et al. Effect of lubiprostone, a unique agent for the treatment of chronic idiopathic constipation, on clinical electrocardiographic results. Gastroenterology. 2007;132:A325. Abstract.
- Corazziari E, Badiali D, Bazzocchi G, et al. Long-term efficacy, safety, and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46:522–526. CrossRef
- Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic Constipation
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Digestive Diseases and Sciences
Volume 56, Issue 9 , pp 2639-2645
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Chronic idiopathic constipation
- Long-term safety
- Industry Sectors
- Author Affiliations
- 1. Division of Gastroenterology, Harvard Medical School, 330 Brookline Ave., DA-501, Boston, MA, USA
- 2. College of Medicine, University of Illinois, Rockford, IL, USA
- 3. Gastroenterology Section, Temple University, Philadelphia, PA, USA
- 4. Division of Gastroenterology-Hepatology, Carver College of Medicine, University of Iowa, Iowa City, IA, USA
- 5. Oklahoma Foundation for Digestive Research, Oklahoma City, OK, USA
- 6. Sucampo Pharmaceuticals Inc., Bethesda, MD, USA